Literature DB >> 19358311

Identification, characterization and quantification of specific neuropeptides in rat spinal cord by liquid chromatography electrospray quadrupole ion trap mass spectrometry.

Francis Beaudry1, Catherine E Ferland, Pascal Vachon.   

Abstract

Substance P and CGRP play a central role in neuropathic pain development and maintenance. Additionally, dynorphin A is an endogenous ligand of opioid receptors implicated in the modulation of neurotransmitters including neuropeptides, such as substance P and CGRP. This manuscript proposes a method to characterize, identify and quantify substance P, CGRP and dynorphin A in rat spinal cord by HPLC-ESI/MS/MS. Rat spinal cords were collected and homogenized into a TFA solution. Samples were chromatographed using a microbore C(8) 100 x 1 mm column and a 19 min linear gradient (0:100 --> 40:60; ACN:0.2% formic acid in water) at a flow rate of 75 microL/min for a total run time of 32 min. The peptides were identified in rat spinal cord based on full-scan MS/MS spectra. Substance P, CGRP and dynorphin A were predominantly identified by the presence of specific b CID fragments. Extracted ion chromatogram (XIC) suggested selected mass transitions of 674 --> [600 + 254], 952 --> [1215 + 963] and 717 --> [944 + 630] for substance P, CGRP and dynorphin A can be used for isolation and quantitative analysis. A linear regression (weighted 1/x) was used and coefficients of correlations (r) ranging from 0.990 to 0.999 were observed. The precision (%CV) and accuracy (%NOM) observed were 10.9-14.4% and 8.9-14.2%, 8.8-13.0% and 91.0-110.2% and 97.2-107.3% and 91.8-97.3% for substance P, CGRP and dynorphin A respectively. Following the analysis of rat spinal cords, the mean endogenous concentrations were 110.7, 2541 and 779.4 pmol/g for substance P, CGRP and dynorphin A respectively. The results obtained show that the method provides adequate figures of merit to support targeted peptidomic studies aimed to determine neuropeptide regulation in animal neuropathic and chronic pain models. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358311     DOI: 10.1002/bmc.1206

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  5 in total

1.  Quantitative mass spectrometry analysis reveals that deletion of the TRPV1 receptor in mice alters substance P and neurokinin A expression in the central nervous system.

Authors:  Floriane Pailleux; Jérôme Lemoine; Francis Beaudry
Journal:  Neurochem Res       Date:  2012-08-10       Impact factor: 3.996

Review 2.  Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research.

Authors:  Anca-Narcisa Neagu; Madhuri Jayathirtha; Emma Baxter; Mary Donnelly; Brindusa Alina Petre; Costel C Darie
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

3.  Alleviation of chronic neuropathic pain by environmental enrichment in mice well after the establishment of chronic pain.

Authors:  Pascal Vachon; Magali Millecamps; Lucie Low; Scott J Thompsosn; Floriane Pailleux; Francis Beaudry; Catherine M Bushnell; Laura S Stone
Journal:  Behav Brain Funct       Date:  2013-06-07       Impact factor: 3.759

4.  Mass Spectrometry in Pharmacokinetic Studies of a Synthetic Compound for Spinal Cord Injury Treatment.

Authors:  María Sánchez-Sierra; Isabel García-Álvarez; Alfonso Fernández-Mayoralas; Sandra Moreno-Lillo; Gemma Barroso García; Verónica Moral Dardé; Ernesto Doncel-Pérez
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

5.  Concurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) model.

Authors:  Colombe Otis; Julie Gervais; Martin Guillot; Julie-Anne Gervais; Dominique Gauvin; Catherine Péthel; Simon Authier; Marc-André Dansereau; Philippe Sarret; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Francis Beaudry; Eric Troncy
Journal:  Arthritis Res Ther       Date:  2016-06-23       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.